Advertisement
MRI scans of a wholesome mind (left) and a mind with amyloid plaque deposits (proper), an indication of Alzhiemer’s illness
MARK AND MARY STEVENS NEUROIMAGING AND INFORMATICS INSTITUTE/SCIENCE PHOTO LIBRARY
Some hailed 2023 as the start of a turning level in our efforts to fight Alzheimer’s disease. Two international locations – the US and Japan – accredited a drug known as lecanemab, the primary therapy that truly slows the situation’s development, quite than simply easing its signs. Many different international locations, together with the UK and Australia, at the moment are contemplating following swimsuit, however the drug isn’t with out its critics.
Advertisement
Lecanemab gained approval in…
Source link
